Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Accumulated Expenses (2020 - 2026)

Rani Therapeutics Holdings' Accumulated Expenses history spans 7 years, with the latest figure at $4.7 million for Q1 2026.

  • On a quarterly basis, Accumulated Expenses rose 105.95% to $4.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $4.7 million, a 105.95% increase, with the full-year FY2025 number at $3.9 million, up 323.52% from a year prior.
  • Accumulated Expenses came in at $4.7 million for Q1 2026, up from $3.9 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $4.7 million in Q1 2026, with the low at $69000.0 in Q4 2022.
  • Historically, Accumulated Expenses has averaged $2.6 million across 5 years, with a median of $2.6 million in 2025.
  • Biggest five-year swings in Accumulated Expenses: tumbled 95.19% in 2022 and later skyrocketed 353.62% in 2023.
  • Year by year, Accumulated Expenses stood at $69000.0 in 2022, then surged by 353.62% to $313000.0 in 2023, then surged by 197.44% to $931000.0 in 2024, then skyrocketed by 323.52% to $3.9 million in 2025, then rose by 19.35% to $4.7 million in 2026.
  • Business Quant data shows Accumulated Expenses for RANI at $4.7 million in Q1 2026, $3.9 million in Q4 2025, and $2.1 million in Q3 2025.